Evaluation Value of PD-L1,miR-29a,miR let-7a in the Prognosis of Triple Negative Breast Cancer Patients
Objective To investigate the clinical value of programmed death protein ligand-1(PD-L1),microRNA-29a(miR-29a),microRNA let-7a(miR let-7a)in the prognosis evaluation of triple negative breast cancer(TNBC)patients.Methods 67 patients with TNBC were selected as the observation group,while 67 patients with benign breast tumors admitted during the same period were selected as the control group.All patients were collected and tested for PD-L1 expression levels,and 5 ml of fasting venous blood was collected.Real time fluorescence quantitative PCR was used to measure the expression of miR-29a and miR let-7a,and the relationship between PD-L1,miR-29a,and miR let-7a and their clinical pathological characteristics and prog-nosis was analyzed.Results That the PD-L1 positive rate,miR-29a expression level,and miR let-7a expression level in the ob-servation group were higher than those in the control group.The clinical stage Ⅲ and lymph node metastasis rate in the PD-L1 positive group were higher than those in the PD-L1 negative group.The expression levels of miR-29a and miR let-7a in clinical stage Ⅲ and lymph node metastasis patients were higher than those in clinical stage Ⅰ～Ⅱ and patients without lymph node me-tastasis,and the difference was statistically significant(P＜0.05);After a 3-year follow-up,the survival rate of 67 patients was 59.70％(40/67);The survival rate of PD-L1 positive patients was lower than that of PD-L1 negative patients,and the expression levels of miR-29a and miR let-7a in survivors were lower than those in the death group,with statistically significant differences(P＜0.05).Conclusion PD-L1,miR-29a,and miR let-7a are highly expressed in TNBC,closely related to clinical staging and lymph node metastasis.Patients with high expression have a lower survival rate,and can be used as important prognostic indicators for clinical evaluation.
Triple negative breast cancerProgrammed death protein ligand-1Pathological characteristicsPrognosisClinical value
万方数据
维普
